tbuckley/cabot-search huggingface dataset:
Half of UK patients taking drugs for epilepsy continue to have seizures
Authors: R. Dobson
Journal: BMJ (2004)

Almost half of patients taking drugs for epilepsy continue to have seizures, a survey of patients in the United Kingdom has shown.

Better medical care might improve the lives of people with epilepsy by achieving better seizure control, say the authors of the study in the journal Seizure, published online ahead of print (www.harcourt-international.com/journals/seiz/).

The study, which looked at frequency patterns of seizure among users of epilepsy drugs, was based on the experiences—reported in a questionnaire—of a sample of 1652 patients from across the United …
Growth of Forty-Three Allergic Children during Cortisone Administration
Authors: Lewis Webb Hill
Journal: New England Journal of Medicine (1955)

WHEN I began to treat certain allergic children with cortisone, Dr. Nathan B. Talbot, of the Massachusetts General Hospital, told me that this hormone might retard their growth. Table 1 shows the growth of 43 such children (32 with asthma and 11 with eczema) six months to twelve years of age. The duration of treatment varied between three and thirty months; 15 patients were treated for more than twelve months. No child was given over 75 mg. of cortisone a day; only 1 received as much as this for longer than ten days. The usual maintenance dose varied between 25 and 50 . . .
Chaparral and Liver Toxicity-Reply
Authors: Dafna Gordon
Journal: JAMA (1995)

ABSTRACT In Reply. —We appreciate the comments generated by our report of a patient with chaparral-induced hepatotoxicity who required treatment with liver and kidney transplantation. All of the respondents called for increased precision in the use of terms referring to medications prepared from plants. We agree. Dr Stashower and Mr Torres correctly point out that plants generally referred to as chaparral are not true herbs. It would have been more correct if we had referred to the tablets our patient ingested as coming from botanical or plant sources. Although physicians often refer to medications and other treatments derived from plants as herbal preparations, more careful attention to plant taxonomy is appropriate because of the growing use of alternative remedies.We used the term chaparral to refer to the medication our patient ingested, and we suspect that most preparations are composed mainly of L tridentata species. As Dr Ippen notes, NDGA, one
1-Antitrypsin deficiency {middle dot} 2: Genetic aspects of 1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk
Authors: D L DeMeo
Journal: Thorax (2004)

The genetic aspects of AAT deficiency and the variable manifestations of lung disease in PI Z individuals are reviewed. The role of modifying genetic factors which may interact with environmental factors (such as cigarette smoking) is discussed, and directions for future research are presented.
Watson-Jones Fractures and Joint Injuries
Authors: John D. Hsu
Journal: JAMA (1984)

The multiauthored sixth edition of Watson-Jones' textbook on fracture and joint injuries, edited by J. N. Wilson, ChM, FRCS, continues to be a reference text for surgeons treating acute trauma patients and for orthopedists treating both fractures and joint injuries. It should also be read by physicians providing continuing care for the resultant disabilities from trauma and by medical students as the basic textbook on trauma. The illustrations and diagrams are excellent. Many of the black-and-white pictures of the fifth edition have been replaced by vivid color pictures frequently associated with earlier editions of this classic textbook. The "flaps" of earlier editions, which were important in teaching the salient points and helping the reader retain the material, have not returned with this edition and, with changes in printing techniques, may never come back. As in previous editions, many roentgenograms are used and most are perfect or almost perfectly reproduced. The
Semaphorin 3d signaling defects are associated with anomalous pulmonary venous connections
Authors: Karl Degenhardt, Manvendra K Singh, Haig Aghajanian, Daniele Massera, Qiaohong Wang, Jun Li, Li Li, Connie Choi, Amanda D Yzaguirre, Lauren J Francey, Emily Gallant, Ian D Krantz, Peter J Gruber, Jonathan A Epstein
Journal: Nature Medicine (2013)
TOXICITY OF THE CASTOR BEAN
Authors: F. L. Follweiler
Journal: JAMA (1925)

Certain cases of sensitiveness to the poisonous action of the castor bean have been reported by Arnold,<sup>1</sup>Bernton,<sup>2</sup>Robbins<sup>3</sup>and Snell.<sup>4</sup>A number of such cases developed in connection with experimental and research work involving the use of the castor bean and its products in the Department of Agricultural and Biological Chemistry of the Pennsylvania State College. Much work has been done in this department with the castor bean, particularly with the ricinus lipase. <h3>REPORT OF CASES</h3><h3>Case 1.</h3> —Mr. S., an instructor in the department, during the fall of 1922 contracted what appeared to be a severe cold, marked by violent and continuous sneezing and coughing, with irritation and edema of the mucous membranes of the nose, throat, eyes and ears, together with a dull headache and watering of the eyes. The condition seemed to grow worse instead of improving, and he gradually developed congestion
The Radioisotope Renogram
Authors: Jerry M. Koplowitz
Journal: JAMA (1965)

To determine whether interpretations of radioisotope renograms by qualitative visual inspection were reproducible, a total of 60 randomly assembled renograms, including those of 13 patients with proved unilateral renal hypertension, were subjected to reinterpretation by the initial observer. Fifty-six of the interpretations were in complete agreement. All 13 cases of renovascular hypertension were correctly identified both times. When two quantitative methods of interpretation were applied to renograms of the group with unilateral renal hypertension, diagnostic accuracy was significantly decreased.
Macrophage Inflammatory Protein Derivative ECI301 Enhances the Alarmin-Associated Abscopal Benefits of Tumor Radiotherapy
Authors: Shiro Kanegasaki, Kouji Matsushima, Kenshiro Shiraishi, Keiichi Nakagawa, Tomoko Tsuchiya
Journal: Cancer Research (2014)

Radiotherapy can produce antitumor benefits beyond the local site of irradiation, an immune-based phenomenon known as the abscopal effect, but the mechanisms underlying these benefits are poorly understood. Preclinical studies of ECI301, a mutant derivative of macrophage inhibitory protein-1α, have shown that its administration can improve the antitumor effects of radiotherapy in a manner associated with a tumor-independent abscopal effect. In this article, we report that i.v. administration of ECI301 after intratumoral injection of tumor cell lysates can inhibit tumor growth, not only at the site of injection but also at nontreated sites. Effects of the tumor lysate were further recapitulated by intratumoral injection [corrected] of the alarmins HSP70 or HMGB1, but not HSP60, and i.v. administration [corrected] of ECI301 + HSP70 were sufficient to inhibit tumor growth. Although i.v. administration [corrected] of ECI301 + HMGB1 did not inhibit tumor growth, we found that administration of a neutralizing HMGB1 antibody neutralized the cooperative effects of ECI301 on tumor irradiation. Moreover, mice genetically deficient in TLR4, an immune pattern receptor that binds alarmins, including HMGB1 and HSP70, did not exhibit antitumor responses to irradiation with ECI301 administration. Although ECI301 was cleared rapidly from peripheral blood, it was found to bind avidly to HSP70 and HMGB1 in vitro. Our results suggest a model in which sequential release of the alarmins HSP70 and HMGB1 from a tumor by irradiation may trap circulating ECI301, thereby licensing or restoring tumor immunosurveillance capabilities of natural killer cells or CD4(+) and CD8(+) T cells against tumor cells that may evade irradiation. Cancer Res; 74(18); 5070-8. ©2014 AACR.
Effect of prolonged cimetidine therapy on gastric acid secretion in man.
Authors: G O Barbezat, S Bank
Journal: Gut (1978)

In a double blind trial, 23 patients with endoscopically confirmed duodenal ulceration received cimetidine (300 mg four times daily in six patients, or 400 mg four times daily in 10 patients) or placebo (seven patients) for six weeks. Before entry into the trial, pentagastrin (6 microgram.kg-1.h-1)--stimulated gastric acid secretion after a single oral dose of 300 or 400 mg cimetidine was lowered by 82.1% and 81.0%, respectively, while no significant inhibition was recorded in the patients receiving placebo (8.8%). The same test repeated after six weeks of continuous treatment showed that the effect of the drug was maintained, the percentage inhibition of acid secretion being of the same order as in the first test.
TOXOPLASMIC ENCEPHALITIS IN CHILDREN
Authors: ALBERT B. SABIN
Journal: JAMA (1941)

It has been abundantly demonstrated in recent years that acute nonsuppurative encephalitis is a syndrome of multiple etiology. My purpose in the present communication is (1) to present evidence that organisms of the genus Toxoplasma can be the cause of such encephalitis in children, (2) to describe the clinical and pathologic appearances and (3) to indicate the steps which can be taken to establish the diagnosis. <h3>PRESENT STATUS OF TOXOPLASMA</h3> Toxoplasma is a genus of protozoan parasites which were first observed in the gondi (North African rodent) in 1908 by Nicolle and Manceaux,<sup>1</sup>who differentiated it from Leishmania, and independently in the same year in the rabbit (Brazil) by Splendore.<sup>2</sup>They are highly organized parasites consisting of distinct cytoplasm and nuclear chromatin and are crescentic, pyriform, oval or round, measuring 6 to 7 microns in length and 2 to 4 microns in width, depending on the stage of
Effect of LDL Modified by Myeloperoxidase-H2O2-Cl− System on Intracellular Cyclic Guanosine Monophosphate Level of Endothelial Cells: A Link to Erectile Dysfunction?
Authors: Thierry Roumeguère, Karim Zouaoui Boudjeltia, Michel Vanhaeverbeek
Journal: European Urology (2008)
Reply to the letter of Dr. Gerke
Authors: F. Gleeson, M. Levy, G. Papachristou, M. Pelaez-Luna, E. Rajan, J. Clain, M. Topazian
Journal: Endoscopy (2008)

We thank Dr. Gerke for his letter, his contribution, and his continued interest in this area. Indeed, we referred to his paper [1] twice in our own manuscript [2]. It is notable that our two groups independently reported visualization of celiac ganglia during EUS [1] [3] and have now also described a similar frequency of ganglia visualization [1] [2]. We hope that together we will continue to explore and investigate the diagnostic [4] and therapeutic [5] potential of EUS-guided access to celiac ganglia.
PROGNOSIS OF ACUTE DECOMPENSATED HEART FAILURE IN PATIENTS WITH PRESERVED AND REDUCED LEFT VENTRICULAR EJECTION FRACTION BASED ON N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE AT ADMISSION
Authors: Reynie Leonel Reinoso Gonell, Alexandra Arias-Mendoza, Julio Sandoval Zarate, Hector Gonzalez Pacheco, Carlos R. Martinez Sanchez, Amada Alvarez Sangabriel, Francisco Azar Manzur, Jose L. Briseno de la Cruz, Daniela Leon Hernandez
Journal: Journal of the American College of Cardiology (2014)
Efficacy of Oral Ondansetron in the Prevention of Emesis in Outpatients Receiving Cyclophosphamide-based Chemotherapy
Authors: Thomas M. Beck
Journal: Annals of Internal Medicine (1993)

Objective: To evaluate the efficacy and safety of oral ondansetron (Zofran) as an antiemetic in patients receiving cyclophosphamide-based chemotherapy. Design: A multicenter, randomized, double-blind, stratified, placebo-controlled trial conducted between March 1989 and January 1990. Setting: Twenty-seven oncology centers including university hospitals, community cancer centers, and private medical oncology practices. Patients: A total of 349 chemotherapy-naive patients having their first cycle of cyclophosphamide (≥ 450 mg/m2)-based chemotherapy. Patients also received methotrexate (≥ 30 mg/m2) or doxorubicin (≥ 35 mg/m2). All patients were evaluated for safety and 318 (91%) were evaluated for efficacy. Interventions: Patients were randomly assigned to one of four treatment groups: placebo, 1 mg, 4 mg, or 8 mg of ondansetron. Assigned study medication was taken three times per day for 3 consecutive days. Measurements: Time and number of emetic episodes as well as degree of nausea were recorded by patients for each of the 3 study days. Results: Compared with placebo, all three doses of ondansetron were superior (P < 0.001) in preventing vomiting and controlling nausea. A complete response (no emetic episodes) was observed in 19%, 57%, 65%, and 66% of patients in the placebo, 1-mg, 4-mg, and 8-mg ondansetron groups, respectively. For patients who received higher-dose cyclophosphamide and doxorubicin, a dose-related trend in antiemetic efficacy of ondansetron was observed. Mild headache and constipation were the most frequently reported adverse events. No extrapyramidal reactions were observed. Conclusion: Oral ondansetron is a safe and effective antiemetic that is more efficacious than placebo for patients receiving cyclophosphamide-based chemotherapy. * For current author addresses and the members of the study group, see end of text.
Monitoring of tobramycin levels in patients with cystic fibrosis by finger-prick sampling: Figure 1–
Authors: Andrew Jones, Judith Beisty, Diane McKenna, Debbie Clough, Kevin Webb, Julie Morris, Brian Keevil
Journal: European Respiratory Journal (2012)

to systemic inflammation, as expressed by increased IgG and resulting from colonisation with pathogens and irrespective of blood pressure or diabetes status.Conversely, in adult CF patients, CFRD seems to influence arterial stiffness [4].This discrepancy between adults and children may indicate
Radiologically Occult Pulmonary Lymphangitic Carcinomatosis Detected by ^67Gallium-Citrate Scintiscan
Authors: PIERRE R. BAND
Journal: Annals of Internal Medicine (1976)

Letters1 October 1976Radiologically Occult Pulmonary Lymphangitic Carcinomatosis Detected by 67Gallium-Citrate ScintiscanPIERRE R. BAND, M.D., BRIAN C. LENTLE, M.D., ROGER AMY, M.D., RAUL C. URTASUN, M.D., FRANK A. HERBERT, M.D.PIERRE R. BAND, M.D.Search for more papers by this author, BRIAN C. LENTLE, M.D.Search for more papers by this author, ROGER AMY, M.D.Search for more papers by this author, RAUL C. URTASUN, M.D.Search for more papers by this author, FRANK A. HERBERT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-85-4-476 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe occurrence of pulmonary lymphangitic carcinomatosis with normal chest roentgenogram is well documented (1). Although it is recorded that scintiscans with 131sodium iodide may detect radiologically occult metastases from thyroid carcinoma (2), the detection by 67gallium (Ga) scintiscanning of pulmonary lymphangitic carcinomatosis from breast cancer in a patient with normal radiograph is of note.A 32-year-old white woman underwent a right radical mastectomy followed by radiation therapy to the right supraclavicular and parasternal areas for the treatment of a stage I adenocarcinoma of the breast. Seven years later, the patient developed a right pleural effusion showing malignant cells on cytology....References1. ALKALAYFAIRFAXBULLARD ICJ: Lymphangitic carcinomatosis of the lungs with normal appearing chest X-ray films. Chest 62:229-230, 1972 CrossrefMedlineGoogle Scholar2. TURNERWEIR JC: Pulmonary metastases from thyroid carcinoma detectable only by 131I scan. Treatment and response. J Nucl Med 13:852-855, 1972 MedlineGoogle Scholar3. KHURANAMISHKINNIDEN MFA: Use of gallium to predict inflammatory activity in diffuse interstitial lung disease (abstract). Chest 68:416, 1975 Google Scholar4. SIENSENGRIEBESARGENT JSE: Gallium-67 scintigraphy of pulmonary diseases as a complement to radiography. Radiology 118:371-377, 1976 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Department of Medicine, Pathology and Radiology University of Alberta Department of Nuclear Medicine W.W. Cross Cancer Institute Edmonton, Alberta AB T6G 2G3 Canada PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPulmonary Lymphangitic Carcinomatosis (PLC): Spectrum of FDG-PET FindingsPulmonary lymphangitic carcinomatosis from hypopharyngeal adenosquamous carcinoma 1 October 1976Volume 85, Issue 4Page: 476-477KeywordsBreast cancerCarcinomatosisCell biologyCellsLung and intrathoracic tumorsPatient advocacyPleural effusionRadiation therapyThoraxThyroid carcinoma Issue Published: 1 October 1976 PDF DownloadLoading ...
Bertilaccio MT, Simonetti G, Dagklis A, et al. Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. Blood. 2011;118(3):660–669.
Authors: Maria Teresa Sabrina Bertilaccio, Giorgia Simonetti, Antonis Dagklis, Martina Rocchi, Tania Veliz Rodriguez, Benedetta Apollonio, Alberto Mantovani, Maurilio Ponzoni, Paolo Ghia, Cecilia Garlanda, Federico Caligaris-Cappio, Marta Muzio
Journal: Blood (2012)
The Uncertainty of Hair Analysis for Trace Metals
Authors: Steven J. Steindel
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-<i>cis</i> Retinoic Acid–Mediated Differentiation in Neuroblastoma
Authors: Nilay Shah, Jianjun Wang, Julia Selich-Anderson, Garrett Graham, Hasan Siddiqui, Xin Li, Javed Khan, Jeffrey Toretsky
Journal: Clinical Cancer Research (2014)

Neuroblastoma is an embryonic childhood cancer with high mortality. 13-cis retinoic acid (13-cisRA) improves survival for some patients, but many recur, suggesting clinical resistance. The mechanism of resistance and the normal differentiation pathway are poorly understood. Three-amino-acid loop extension (TALE) family genes are master regulators of differentiation. Because retinoids promote differentiation in neuroblastoma, we evaluated TALE family gene expression in neuroblastoma.We evaluated expression of TALE family genes in RA-sensitive and -resistant neuroblastoma cell lines, with and without 13-cisRA treatment, identifying genes whose expression correlates with retinoid sensitivity. We evaluated the roles of one gene, PBX1, in neuroblastoma cell lines, including proliferation and differentiation. We evaluated PBX1 expression in primary human neuroblastoma samples by qRT-PCR, and three independent clinical cohort microarray datasets.We confirmed that induction of PBX1 expression, and no other TALE family genes, was associated with 13-cisRA responsiveness in neuroblastoma cell lines. Exogenous PBX1 expression in neuroblastoma cell lines, mimicking induced PBX1 expression, significantly impaired proliferation and anchorage-independent growth, and promoted RA-dependent and -independent differentiation. Reduced PBX1 protein levels produced an aggressive growth phenotype and RA resistance. PBX1 expression correlated with histologic neuroblastoma subtypes, with highest expression in benign ganglioneuromas and lowest in high-risk neuroblastomas. High PBX1 expression is prognostic of survival, including in multivariate analysis, in the three clinical cohorts.PBX1 is an essential regulator of differentiation in neuroblastoma and potentiates retinoid-induced differentiation. Neuroblastoma cells and tumors with low PBX1 expression have an immature phenotype with poorer prognosis, independent of other risk factors.
Research with immunoactive agents
Authors: Phil Gunby
Journal: JAMA (1981)

<h3>Update on thymosin</h3> Medicine is entering an age of immunopharmacology, says Allan L. Goldstein, PhD, codiscoverer of thymosin, a semipurified extract of the thymus gland. Goldstein now is professor and chairman of the Department of Biochemistry, George Washington University Medical Center, Washington, DC. He and the late Abraham White, PhD, isolated thymosin at Albert Einstein College of Medicine, New York, in 1965. Today, according to Goldstein, in addition to trials sponsored by the National Cancer Institute (NCI) at five centers, more than 150 other research teams in the United States and Europe are testing thymosin's effectiveness at stimulating T lymphocyte immune responses in animals and plants with cancer, infectious diseases, and other disorders associated with immune suppression or imbalance (<i>JAMA</i>[MEDICAL NEWS] 1977;237:429-438). So far, Goldstein told an American Cancer Society seminar in Daytona Beach, Fla, two randomized trials have been completed with thymosin fraction 5, which contains a family
Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: An in vivo nuclear magnetic resonance study
Authors: Beat M. Jucker, Thomas R. Schaeffer, Robin E. Haimbach, Matthew E. Mayer, Derek H. Ohlstein, Stephen A. Smith, Alexander R. Cobitz, Susanta K. Sarkar
Journal: Metabolism (2003)
Endoscopic Hemoclip Treatment for Gastrointestinal Bleeding
Authors: K. F. Binmoeller, F. Thonke, N. Soehendra
Journal: Endoscopy (1993)

We conducted an uncontrolled study to evaluate an improved metallic clip (Olympus hemoclip) for the endoscopic treatment of nonvariceal gastrointestinal bleeding. A total of 88 patients (mean age 63 +/- 14, 60 males) with bleeding from a wide range of sources were treated. Seventy-eight patients had active bleeding (spurting in 50, oozing in 28) and 10 patients had a nonbleeding visible vessel. Initial hemostasis was achieved in all patients with active bleeding. A total of 255 clips were placed (average of 2.9 clips per patient, range of 1-10 clips). Spurting arterial bleeders required more clips on average than oozing bleeders (3.2 versus 2.7); active bleeders required more clips than cases with nonbleeding visible vessels (3.0 versus 2.2). Mean follow-up was 397 +/- 148 days. Recurrent bleeding was observed in 5 patients, all of whom had active bleeding on initial presentation. Re-bleeding was successfully treated with hemoclips in 4 patients and one patient underwent surgery. Clips appeared to be retained well; early clip dislodgement resulted in rebleeding in only 1 patient. No complications resulted from this treatment. Clips did not impair healing of peptic ulcers. We conclude that endoscopic hemoclip placement is a highly effective and safe method for treating nonvariceal gastrointestinal bleeding and deserves comparative studies with other methods of endoscopic hemostasis.